ClinicalTrials.gov

VERIFIED

## Connections

clinical-trials gene-therapy monitoring

What It Does

Registry of 400,000+ clinical studies worldwide
Trial status, phase, enrollment, results
Sponsor and investigator information
Intervention details (gene therapy vectors, dosing)

How to Use

### Web

1. Go to https://clinicaltrials.gov

2. Search: "STRC hearing loss" or "inner ear gene therapy" or "OTOF"

3. Filter: Phase, Status, Intervention Type

### API


        # Search for hearing gene therapy trials
        curl "https://clinicaltrials.gov/api/v2/studies?query.term=hearing+loss+gene+therapy&format=json&pageSize=20"

### Python


        import requests
        r = requests.get("https://clinicaltrials.gov/api/v2/studies", params={
            "query.term": "hearing loss gene therapy",
            "format": "json",
            "pageSize": 20
        })
        for study in r.json()['studies']:
            proto = study['protocolSection']
            ident = proto['identificationModule']
            status = proto['statusModule']
            print(f"{ident['nctId']}: {ident['briefTitle']} [{status['overallStatus']}]")

Verified Status

VERIFIED — No STRC-specific trials as of 2026-04. Key active hearing gene therapy trials:

NCT06721170: EH002 gene therapy for OTOF hearing loss (RECRUITING)
NCT06517888: anti-VEGF for vestibular schwannoma (RECRUITING)
OTOF trials are proof-of-concept for inner ear AAV delivery — directly relevant to future STRC trials.

STRC Research Usage

STRC Gene Therapy Research — monitoring trial landscape
No STRC trial exists yet (as of 2026-04) — STRC gene therapy is pre-clinical
OTOF trials (NCT06721170 EH002) demonstrate inner ear AAV delivery is feasible → directly relevant for future STRC E1659A therapy
STRC Gene Therapy — tracking progression toward STRC trials
Key trials to monitor: OTOF (proof of concept for inner ear gene therapy), TMC1, GJB2

Results (April 2026)

Sponsor analysis DONE: Decibel/Regeneron (DB-OTO, OTOF), Akouos/Eli Lilly (AK-OTOF), Shanghai EENT/Shu (STRC pre-clinical)
Active trials: NCT06721170 (EH002 OTOF gene therapy, RECRUITING) is most relevant proof-of-concept for inner ear AAV delivery
Next: set up automated alerts, endpoint analysis, eligibility criteria review for future STRC trial design

Results (April 2026)

Sponsor analysis DONE: Decibel/Regeneron (DB-OTO, OTOF), Akouos/Eli Lilly (AK-OTOF), Shanghai EENT/Shu (STRC pre-clinical)
Active trials: NCT06721170 (EH002 OTOF gene therapy, RECRUITING) is most relevant proof-of-concept for inner ear AAV delivery
Next: set up automated alerts, endpoint analysis, eligibility criteria review for future STRC trial design